SLPI expression detected with the polyclonal antibody was not associated with disease-free survival in the whole cohort of stage II and stage III CRC patients (HRR 0.91, P-value 0.60, 95% confidence interval 0.63–1.31, Supplementary Fig. 4c and 4d) or in stage II patients separately (HRR 1.16, P-value 0.61, 95% confidence interval 0.65–2.08, Supplementary Fig. 5a). The gene discussed is SLPI; the disease is colorectal carcinoma.